Test Price
850 AED✅ Home Collection Available
Porphobilinogen (PBG), Qualitative, Urine – Acute Porphyria Screening
Executive Summary & Core Metrics
Clinical Executive Summary
The Porphobilinogen (PBG) Qualitative Urine Test is a definitive first-line biochemical screen for acute intermittent porphyria (AIP) and related acute hepatic porphyrias. Using ISO 9001:2015-accredited column chromatography with spectrophotometric quantification, our laboratory achieves greater than 99% diagnostic sensitivity with same-day reporting when samples arrive by 9 AM on designated collection days. This test is essential for evaluating patients presenting with unexplained severe abdominal pain, neuropsychiatric disturbances, or reddish urine — the classic triad of an acute porphyric attack. Early detection through qualitative PBG screening enables prompt initiation of life-saving hemin therapy and prevents unnecessary surgical interventions.
Service Highlights
- ✓ Home Collection with Cold-Chain Transport (8 AM – 11 PM)
- ✓ ISO-Certified Light-Protected Sample Handling
- ✓ Same-Day Reporting (Tue/Fri by 9 AM Cutoff)
- ✓ Telephonic Post-Test Clinical Guidance
- ✓ Insurance Billing Verification via WhatsApp
- ✓ DHA-Licensed Laboratory (License No. 1143)
Test Overview & Methodology
The Porphobilinogen (PBG) Qualitative Urine Test is a first-tier biochemical assay designed to detect pathologically elevated PBG — the hallmark porphyrin precursor that accumulates in acute intermittent porphyria (AIP), variegate porphyria, and hereditary coproporphyria. This test is indicated when a patient presents with acute neurovisceral symptoms including severe episodic abdominal pain, tachycardia, hypertension, hyponatremia, anxiety, confusion, or seizure activity, particularly when accompanied by dark or port-wine-colored urine. A positive qualitative PBG result warrants immediate quantitative confirmation and genetic testing, but is independently sufficient to initiate hemin therapy while awaiting confirmatory results. Our methodology uses ion-exchange column chromatography to isolate PBG prior to spectrophotometric detection, eliminating cross-reactivity from urobilinogen and drug metabolites that plague older Ehrlich-based methods.
| Parameter | Our PBG Qualitative Test | Alternative (Ehrlich's Reagent Method) |
|---|---|---|
| Methodology | Column Chromatography with Spectrophotometric Detection; LC-MS/MS Confirmation for Equivocal Results | Ehrlich's Aldehyde Reagent; non-specific, cross-reactive with urobilinogen and drug metabolites |
| Analytical Specificity | >99% — PBG isolated via ion-exchange column prior to detection | ~70–80% — frequent false-positives from urobilinogen, indican, methyldopa, phenazopyridine |
| Turnaround Time | Same Day (Sample by 9 AM Tue/Fri) | 24–72 hours (batch processing) |
| Diagnostic Sensitivity (AIP) | >99% during acute attack | 85–90% during acute attack |
| Regulatory Compliance | Fully Compliant — ISO 9001:2015 Accredited | Variable; may lack UAE-specific accreditation |
Physician Insight & Safety Protocols
A Note from Dr. Ajay Singh — DHA License: 36234132
"Acute intermittent porphyria is one of the most frequently missed diagnoses in emergency medicine because its presentation mimics dozens of common conditions such as appendicitis, pancreatitis, and psychiatric disorders. I have evaluated patients who underwent unnecessary laparotomies before a simple urine PBG test revealed the true underlying cause. A positive qualitative PBG during an acute attack must always be correlated with the patient's complete clinical picture — including medication history, menstrual cycle phase in women, fasting status, and recent alcohol intake. Clinicians should never delay hemin therapy while awaiting quantitative results when the clinical suspicion is high and the qualitative screen is positive. Early diagnosis prevents disease progression and reduces morbidity."
Critical Medication Advisory
Medication Safety Notice
Do not discontinue any prescribed medication without consulting your treating physician. Many commonly prescribed drugs — including barbiturates, sulfonamides, certain anticonvulsants (carbamazepine, phenytoin, valproate), rifampicin, and oral contraceptive pills — are known porphyrinogenic agents that can precipitate acute attacks in susceptible individuals. Abrupt discontinuation of anticonvulsants or antihypertensives carries independent life-threatening risks. Always discuss your complete medication list with your physician before testing and provide a full inventory of all prescription and over-the-counter medications to the collection team.
Patient Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Home Collection
- Patient currently experiencing acute severe abdominal pain or altered mental status — proceed directly to emergency department
- Patient with active seizure within the past 24 hours
- Suspected acute porphyric crisis with respiratory compromise or quadriparesis
- Minors under age 18 without legal guardian present
- Patient unable to provide informed consent due to altered cognition
Emergency Red Flags — Seek Immediate Care
- Severe unexplained abdominal pain disproportionate to physical examination findings
- Acute confusion, hallucinations, paranoid ideation, or seizure activity
- Dark reddish-brown or port-wine-colored urine (reported or observed)
- Progressive muscle weakness, ascending paralysis, or bulbar symptoms (dysphagia, dysarthria)
- Severe hyponatremia (serum sodium below 125 mmol/L) with neurological symptoms
- Tachycardia above 120 bpm with labile hypertension unresponsive to initial management
If any of the above are present, do not wait for home collection. Proceed immediately to the nearest emergency department and inform the attending physician of suspected acute porphyria.
Patient FAQ & Clinical Guidance
1. What is a Porphobilinogen (PBG) Qualitative Urine Test and why is it ordered?
The Porphobilinogen Qualitative Urine Test detects elevated PBG in urine to screen for acute intermittent porphyria and related hepatic porphyrias. PBG is a porphyrin precursor that accumulates to toxic levels during acute porphyric attacks, causing severe abdominal pain, neurological dysfunction, and psychiatric disturbances. Your physician orders this test when you present with unexplained recurrent episodes of these symptoms — particularly if accompanied by dark or reddish urine. A positive result provides critical biochemical evidence to initiate targeted therapy and avoid misdiagnosis with conditions such as appendicitis or pancreatitis.
2. Why must the urine sample be collected in a dark-colored container wrapped in foil?
PBG is highly light-sensitive and degrades rapidly upon exposure, requiring collection in a dark amber vial wrapped in aluminum foil for transport. Even brief exposure to ambient or fluorescent light can reduce PBG concentration by up to 50% within 30 minutes, potentially yielding a false-negative result that misses a life-threatening acute porphyric attack. This strict light-protection protocol is an international laboratory standard mandated by DHA guidelines for porphyrin precursor testing and is not optional. Our home collection kit includes a dark amber collection cup and aluminum foil wrapping instructions.
3. How should I prepare for the PBG urine test and when will I receive results?
No fasting is required but you must avoid alcohol for at least 48 hours prior to collection and inform your physician about all current medications. Alcohol is a potent porphyrinogenic trigger that can precipitate acute attacks. Provide a complete list of all prescription drugs, over-the-counter medications, herbal supplements, and hormonal preparations to the collection team. Results are reported the same day when samples are received by 9 AM on Tuesday or Friday. Our telephonic clinical guidance service ensures you receive your results with expert interpretation within hours of sample processing.
4. What does a positive PBG result mean for my health?
A positive qualitative PBG result indicates that you are likely experiencing an acute porphyric attack and requires immediate medical intervention. Your physician will initiate hemin therapy to suppress hepatic porphyrin synthesis and will order confirmatory quantitative testing along with genetic analysis for definitive diagnosis. Treatment during an acute attack focuses on symptom management, avoidance of porphyrinogenic drugs, and supportive care. Long-term management includes genetic counseling, lifestyle modifications to avoid triggers, and regular monitoring. Most patients with AIP lead normal lives between attacks with appropriate preventive measures.
5. Can I have this test done at home and how does the collection process work?
Yes, home collection is available for this test daily from 8 AM to 11 PM. Our trained phlebotomy team will deliver the collection kit which includes a dark amber urine cup, aluminum foil for light protection, and cold-pack transport materials. You will provide a random urine sample following the light-protection protocol provided. The sample is then transported via ISO-certified cold chain to our DHA-licensed laboratory in Dubai Healthcare City. Results are communicated via WhatsApp and phone call with clinical interpretation by our medical team. Please note that if you have severe symptoms such as acute abdominal pain or altered mental status, you should proceed to the emergency department rather than wait for home collection.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection Framework
Data Privacy & Health Information
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — governing all patient data collection, processing, and storage
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — regulating electronic health records and telemedicine
- Federal Decree-Law No. 4 of 2016 on Medical Liability — governing clinical testing safety, patient consent, and professional accountability
Laboratory Accreditation
- ISO 9001:2015 Quality Management System Certification
- DHA Facility License No. 1143
- Clinical Oversight: Dr. Ajay Singh (DHA Registration ID: 36234132)
- All laboratory personnel are DHA-licensed and bound by strict confidentiality agreements
Patient data is encrypted during transmission and stored in UAE-based secure servers in compliance with PDPL requirements. Results are disclosed only to the ordering physician and the patient through verified communication channels. Patients have the right to access, correct, or request deletion of their personal data per PDPL Article 7.
Clinical & Logistical Metadata
| Test Name | Porphobilinogen (PBG), Qualitative, Urine |
| Price (AED) | 850 |
| Turnaround Time | Same Day (Sample by 9 AM Tue/Fri) |
| Sample Type / Matrix | Random Urine — Light-Protected Collection (Dark Amber Vial Wrapped in Foil) |
| Methodology Used | Column Chromatography with Spectrophotometric Detection; LC-MS/MS Confirmation for Equivocal Results |
| ICD-10-CM Code | E80.2 (Acute Intermittent Porphyria), E80.1 (Variegate Porphyria), E80.0 (Hereditary Coproporphyria), Z15.89 (Genetic Susceptibility) |
| LOINC Code | 2811-5 — Porphobilinogen [Presence] in Urine |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians